How 2026 State Employee Health Plans Are Deciding Whether to Include Zepbound and Wegovy After Updated GLP‑1 Cost‑Effectiveness Reviews
Data first. As of March 2026, at least 19 state employee health plans have re‑evaluated coverage for glucagon‑like peptide‑1 receptor agonists (GLP‑1s) such as tirzepatide (brand name Zepbound, Eli Lilly) and semaglutide (brand name Wegovy, Novo Nordisk). According to the National Association of State Personnel Executives’ benefits survey, 11 states now cover at least one GLP‑1 for chronic weight management, while 8 have limited coverage to diabetes indications only. Another 12 are reviewing their 2026 plan year formularies following updated cost‑effectiveness reports from the Institute for Clinical and Economic Review (ICER) released in January 2026.
The Numbers Behind New Cost Benchmarks
ICER’s 2026 update re‑set cost‑effectiveness thresholds using long‑term cardiovascular outcome data published in 2025. Zepbound’s cost per quality‑adjusted life year (QALY) came in around $148,000 and Wegovy’s at $172,000, based on average net prices after manufacturer rebates but before employer rebates. Most state employee health plans still use a target range of $100,000 to $150,000 per QALY, consistent with CMS and 2025 ACA Marketplace benchmark plan assumptions. That creates a tension: the numbers say “borderline value,” but the demand keeps climbing.
Several states, including North Carolina, Colorado, and Minnesota, have commissioned actuarial modeling to see what that actually means for their budgets. Early findings from Minnesota’s Management and Budget office show that adding GLP‑1 coverage for obesity could raise combined medical and pharmacy spend by about 3.4 percent a year, even after accounting for downstream savings in cardiovascular and diabetes care. The expected first‑year utilization rate is 5 to 7 percent of eligible employees, higher than many predicted a year ago.
How Tier Placement Shapes Access
In 2026 plan filings, Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide 2.5-15 mg) usually fall into tier 4 or tier 5 specialty categories. Translation: members pay a 25-50 percent coinsurance instead of a simple copay. Some state plans now cap out‑of‑pocket liability per fill to match the $2,000 annual out‑of‑pocket ceiling created by the Inflation Reduction Act rules taking effect for public employee plans this January. For diabetes treatment, the same substances, Ozempic (semaglutide) and Mounjaro (tirzepatide), stay in tier 3 brand‑preferred status, since the ADA standards of care all but require access there.
| Drug | Generic Name | Manufacturer | Common Tier (2026 Plans) | Primary Indication Covered |
|---|---|---|---|---|
| Zepbound | Tirzepatide | Eli Lilly | Tier 4-5 (Specialty) | Weight management (variable coverage) or Type 2 diabetes (commonly covered) |
| Wegovy | Semaglutide | Novo Nordisk | Tier 4-5 (Specialty) | Weight management (variable coverage) |
| Mounjaro | Tirzepatide | Eli Lilly | Tier 3 | Type 2 diabetes |
| Ozempic | Semaglutide | Novo Nordisk | Tier 3 | Type 2 diabetes |
Employer Cost Pressure and Outcome Experiments
Budget forecasting drives everything here. GLP‑1 uptake across large employer groups jumped nearly 60 percent between 2024 and 2025, according to the 2025 Express Scripts Drug Trend Report. That pace forced states to confront whether health gains justify the price tag. Self‑funded state plans can tighten coverage by indication or BMI threshold; those in pooled purchasing arrangements are tied to PBM contracts from OptumRx or CVS Caremark that leave less room to maneuver.
Some have borrowed from the VA’s 2025 restricted formulary model, covering semaglutide for weight management only after documented cardiovascular disease and an unsuccessful lifestyle‑change attempt. Others, like California, are taking a more experimental route with a pilot Zepbound benefit starting July 2026, tied to a 12‑month outcomes review. Those members face step‑therapy protocols: metformin or other anti‑obesity agents first, GLP‑1s second. Fair enough, but it’s a complicated dance to manage expectations and cost in one move.
Negotiated Price Ripples from IRA Standards
The Inflation Reduction Act’s negotiated pricing program still targets high‑spend Part D drugs, yet its ripple effects reach into public employee plan bargaining. Zepbound and Wegovy remain off CMS’s negotiated list as of April 2026, but PBMs lean on IRA benchmarks during contract renewals. That pressure has netted 10-15 percent price cuts versus early 2025 deals. The catch? Rebate structures are still murky. Several state auditors have now demanded full post‑rebate transparency before approving 2027 plan budgets, hinting at how fragile trust in PBM math really is.
What All This Means for Patients
For employees, it’s a maze. Two drugs with the same compound, one covered, one not, depending on which diagnosis box their doctor ticks. Prior authorization now demands BMI data, ICD‑10 codes, and proof of behavioral counseling. Extra paperwork for providers, minor frustration for members, but it does discourage off‑label prescribing and keeps plan costs under some control.
These 2026 decisions show a clear shift from excitement to evidence management. States are juggling near‑term budget strain with hopes of preventing long‑term chronic disease complications. Whether obesity‑specific coverage becomes the rule will hinge on future cardiovascular outcomes, whatever ICER’s next benchmark says, and how PBMs price once GLP‑1s join the federal negotiation list later this decade. Look, no one’s pretending this will get simpler, just more public.
Disclaimer: This article is for informational purposes only and does not constitute medical, legal, or insurance advice. Always check your own plan documents or talk with a licensed benefits specialist before making decisions about coverage.